Is Long-Term Stimulant use for ADHD safe?

If your child has been on a stimulant for ADHD for a year or two, you have probably already heard the standard reassurances from their prescribing healthcare provider:

"It's been studied for decades, it's safe, don't worry."

And mostly, that is true. But "mostly safe" is not the same as "no big deal," and the science around what happens after five, ten, or twenty years on a stimulant has gotten a lot more interesting (and a lot more honest) in just the last couple of years.

Here is the bottom line, before we get into the weeds: long-term stimulant therapy is one of the most life-saving interventions in psychiatry. 

It is also not free. 

Children and adults who stay on stimulants for years into adulthood may end up a tiny bit shorter than they would have been otherwise, and are more likely to develop high blood pressure. But at the same time, they are much less likely to die young, develop a substance use problem, or end up depressed. 

That tradeoff is the heart of this conversation. Let's walk through what the recent big studies actually show.

The longevity gap (why we treat in the first place)

ADHD is a chronic, life long condition, and the lifetime trajectory of untreated ADHD is the backdrop for everything else in this post. 

A 2025 matched-cohort study from the UK, looking at more than 30,000 diagnosed adults compared to 300,000 neurotypical controls, found that men with diagnosed ADHD live about 6.78 years less than men without it (73.3 vs 80.0 years), and women with diagnosed ADHD live about 8.64 years less (75.2 vs 83.8 years)¹.

That shortened life span is almost entirely from "unnatural causes": car accidents, accidental poisonings, suicide, and other consequences of unmanaged impulsivity and inattention¹. None of this is a near-term concern for a child in elementary school however. It is the adult trajectory that early, well-managed treatment is trying to change.

And there is direct evidence that treatment does change it. 

A large 2024 Swedish study (Li et al. in JAMA Psychiatry) followed nearly 150,000 newly-diagnosed individuals — including children and adolescents — and found that starting medication within three months of diagnosis was associated with a 21% reduction in all-cause mortality over the next two years, almost entirely driven by a drop in unnatural-cause deaths,² such as the car accidents etc, discussed above. 

So when we talk about long-term side effects below, keep this number in your back pocket — the medication is, on net, protective against accidental or unintentional death.

Cardiovascular: blood pressure is the real story

Stimulants nudge up heart rate and blood pressure. We have known this for decades. The new question is what happens when you do that for fifteen years?

Most of what follows comes from adult registry data — the cumulative effects are by definition something a child accumulates over many years of treatment. None of it describes a instant risk for a 7-year-old starting Ritalin or Adderall, for example. 

What it does describe is the trajectory a long-term treatment plan needs to keep an eye on, as the child develops and grows. Blood pressure checks at your child's visits are calibrated to what is normal for a kid their size and help us keep track of any increases in readings over time.

Research suggests that after five or more years of continuous use of an ADHD stimulant medication, the risk of being diagnosed with hypertension is roughly 80% higher than in untreated peers. 

But there are caveats associated with the above statement worth knowing:

• The risk only became statistically significant at doses above about 1.5× the standard daily dose³. Conservative dosing genuinely matters, which is why using the lowest effective dose is so important when medicating children as this will reduce the risk of the meication causing hypertension.

• Big meta-analyses across nearly 4 million participants have not found any link between stimulants and heart attacks, strokes, heart failure, arrhythmias, or thromboembolic disease⁴. Those findings are clean and reassuring.

One causal caveat that matters here. This is observational data. People who stay on stimulants for 5+ years are not a random sample — they tend to have more severe, more impairing ADHD, and severe ADHD is itself independently associated with cardiovascular risk²⁰ as ADHD is typically associated with unhealthy lifestyle choices such as poor food choices and smoking for example. Those with ADHD also typically struggle with chronic daily stress, which also impacts heart health in the long run.

Growth: a real short-term effect, a contested long-term one

The short version: stimulants slow how quickly a child grows during active treatment. This is consistent across MTA, ADDUCE, Harstad, and basically every prospective dataset. 

Over the first three years on a stimulant, MTA (Multimodal Treatment of ADHD study) found a cumulative height deficit of about 2 cm (roughly 0.67 cm per year), along with weight loss from appetite suppression⁶. 

The harder question is whether that early deceleration translates into a permanent reduction in adult height. 

The literature is genuinely split.

The Multimodal Treatment Study of ADHD study (MTA) followed 579 children for 16 years into adulthood. As adults, the whole ADHD cohort was about 1.29 cm shorter than matched local controls. 

The groups were split into those kids who used their stimulants at least 50% or more of the time. They were called the “Consistent” subgroup.

The “Inconsistent” subgroup were those kids who used their stimulant medication some, but not all the time.

The “Negligible” subgroup were those children who barely used their stimulant medications.

Within the cohort, kids who used stimulants consistently or inconsistently were about 2.55 cm shorter than kids who used them negligibly; the "Consistent" subgroup specifically was about 2.74 cm shorter than the "Inconsistent" subgroup⁶.

However, we have few caveats moms need to consider before treating this argument as settled:

• The "Consistent" subgroup involved 53 people. Only. 

  That's a small fraction of the original cohort who enrolled, 9% to be exact, who self-selected over 16 years (the randomized design ended at 14 months — everything after is observational). The permanent-height-loss claim rides on a small, non-randomly-assembled group of people.

• One group was already taller than the other before starting medication

  Swanson et al. note in the same paper that kids who ended up in the negligible group were already about 1 cm taller at baseline, before any prospective treatment⁶. So some of the apparent height "suppression" was a preexisting between-group difference, not a direct drug effect.

• Bigger, population-based studies have not consistently replicated the results

  Harstad et al. 2014 (Rochester Epidemiology Project) found no significant effect of stimulants on final adult height²¹. The Faraone 2008 meta-analysis also showed no differences²². A recent qualitative review (Carucci et al. 2024) showed that the medicated participants ended up barely below the average height for the population²³.

The honest read is possibly real, not established, and if real, a small loss in height when we use ADHD stimulant medications. For a kid already at the very short end of the curve, that's worth a conversation with thier healthcare provider. However, for most kids, it doesn't justify withholding effective treatment that otherwise provides such a life changing improvements in quality of life.

Ok, but as a precaution can we just take drug holidays to protect against any risk of height loss?

Drug holidays — skipping weekends or summers — are used by somewhere between 25% and 70% of families⁸. They help with weight recovery, but they do not rescue small height loss in randomized trials⁹.

The brain: no evidence of damage with ADHD stimulant use

Here is the part that should make you feel better: therapeutic-dose stimulants do not produce the kind of neurotoxicity, or damage to the brain, seen with high-dose recreational methamphetamine abuse. That distinction matters and is well-supported by both animal work and human imaging studies¹⁰.

Beyond that, the story gets fuzzier than the press releases suggest. 

The popular framing — that stimulants "normalize" brain development in ADHD — comes mostly from cross-sectional and retrospective MRI work showing that medicated ADHD patients tend to have more ‘normal’ looking brains than those with ADHD who do not use stimulant medications. The directional finding is real; the causal attribution to medication is not established. In other words we don’t know if these positive brain changes happen purely  because of the medication or because of something else.

A more honest summary: there is no evidence of structural damage from therapeutic dosing of ADHD stimulant medications, and there is possible evidence of beneficial structural effects in the brain when using an ADHD stimulant medication.

Psychiatric effects: the amphetamine/methylphenidate split

Stimulants do carry a black-box warning for psychosis and mania, and that warning is not equal across the two classes.

A study of 1,374 patients hospitalized for first-episode psychosis or mania (Moran et al. 2024, cohort roughly age 16–35) found¹²:

• Recent amphetamine prescription use: 2.68x increased odds of psychosis.

• High-dose amphetamine (>30 mg dextroamphetamine equivalents/day): 5.28x increased odds.

• Recent methylphenidate use: no significant increase in risk of psychosis

For a child or adolescent with a family history of bipolar disorder, prodromal psychotic symptoms, or other psychiatric vulnerability, methylphenidate is the safer first choice. 

In those who are using their ADHD stimulant medication as they are supposed too, psychosis occurs in roughly 1 in 500. By contrast, in those who misuse high doses of ADHD stimulants, the risk is higher, at 1 in every 3 individuals¹³.

On anxiety and depression: despite what the package inserts list, the rigorous meta-analytic evidence shows that ADHD stimulants do not trigger anxiety or depression.

In fact, longitudinal data suggests that when a person is taking their ADHD stimulant medication, this is associated with about a 20% decrease in co-occurring depression and meaningful reductions in self-harm and suicidal behaviors compared to when they are unmedicated¹⁴. The medication treats the underlying executive dysfunction that breeds those secondary mood problems like low mood and anxiety.

Substance use: Current treatment protects against the development of substance use disorders

The old fear was that giving stimulants to kids would "prime" their brains for addiction later. The evidence against this argument is substantial.

Untreated ADHD is a real risk factor for substance use disorders. Recent population-based studies suggest that those with untreated ADHD have a  2–3× higher risk of developing a substance use disorder²⁶ compared to those who are treated.

Treatment with ADHD stimulants appears to reduce that risk. The two studies most often cited:

• A Swedish registry study (Chang et al. 2014) of ~38,000 individuals with ADHD (born between 1960 and 1998) found a 31% reduction in substance-abuse events with stimulant therapy over a 3-year follow-up window¹⁵.

• A within-individual comparison (Quinn et al. 2017) on nearly 3 million U.S. patients found 35% lower odds of substance-related events in men and 31% lower in women during medicated months versus unmedicated months in the same patients¹⁶.

A caveat worth knowing:

• The protection is only there when you are actively using the ADHD stimulant medication. Treatment protects you while you're on it; whether protection persists after stopping is less clear.

The honest summary: stimulants don't appear to increase later SUD risk, and they reliably reduce risk during active treatment. 

So, what do you do with all this?

A few practical takeaways:

• ADHD medications are protective, and improve quality of life. ADHD stimulants reduce accidental deaths in those with ADHD, and improve mood and functioning.

• ADHD medications do not cause substance use disorders in those with ADHD.

• Use the lowest effective dose, to reduce the impact of the hypertension that the ADHD stimulants can cause.

• Take the blood pressure cuff seriously. Once a year is not enough; every six months is the standard.

• Plot the growth curve. Growth velocity slows in the first few years of treatment; whether the deficit persists into adulthood is still questionable, but you only find out by tracking it.

• For high psychiatric-risk individuals, default to methylphenidate. The amphetamine psychosis risk is real and dose-dependent.

  
  

The point of all this is not to scare anyone off of stimulants. Treated ADHD looks better than untreated ADHD on the outcomes that matter most — substance-related harm during active treatment, mood and emotional regulation, and keeping our bodies safe after diagnosis. The point is that "safe enough to use for decades" and "free of meaningful long-term effects" are not the same statement, and the second one is not true. Knowing what to watch for is what makes the first one true.

This site is for general informational purposes only and does not constitute the giving of medical advice. The contents do not constitute the practice of medicine, nursing, or other professional health care services. No provider–patient relationship is formed. Please consult with your child's healthcare provider when considering treatment interventions for children.

References

1. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. British Journal of Psychiatry, 2025.

2. Li L, et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA Psychiatry, 2024.

3. Zhang L, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry, 2024.

4. Zhang L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in ADHD: a systematic review and meta-analysis (>3.9 million participants).

5. American College of Cardiology presentation, 2024 (TriNetX cardiomyopathy data).

6. Greenhill LL, et al. Trajectories of Growth Associated With Long-Term Stimulant Medication in the MTA Study. J Am Acad Child Adolesc Psychiatry, 2020; Swanson JM, et al. J Child Psychol Psychiatry, 2017.

7. Multiple longitudinal studies; ADDUCE European Union study, 2-year naturalistic methylphenidate data.

8. Reviews of drug holiday utilization in pediatric ADHD.

9. Waxmonsky JG, et al. RCT of interventions for growth suppression in children with ADHD treated with CNS stimulants.

10. Hart H, et al. Meta-analysis of fMRI studies of timing in ADHD. Biological Psychiatry / systematic review 2013; Walhovd KB, et al. Prospective longitudinal cortical thickness study in ADHD, 2020; ENIGMA-ADHD mega-analyses; ABCD imaging analyses.

11. Wang GJ, et al. Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with ADHD. PLOS ONE.

12. Moran LV, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines. American Journal of Psychiatry, 2024.

13. Meta-analyses of therapeutic vs. non-therapeutic stimulant psychosis rates.

14. Chang Z, et al. Stimulant ADHD medication and mood and suicidal behavior outcomes.

15. Chang Z, et al. Stimulant ADHD medication and risk for substance abuse. Swedish registry data.

16. Quinn PD, et al. ADHD Medication and Substance-Related Problems. American Journal of Psychiatry, 2017.

17. Misuse and diversion of stimulant medications prescribed for ADHD: a systematic review. Frontiers in Psychiatry, 2025.

18. Wolraich ML, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents. Pediatrics, 2019 (AAP); HEDIS quality measure CMS136v15 (Follow-up Care for Children Prescribed ADHD Medication), NCQA/CMS.

19. NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management.

20. Li L, et al. Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort study. World Psychiatry, 2022.

21. Harstad EB, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics, 2014.

22. Faraone SV, et al. Effect of stimulants on heights and weights: a review of the literature. J Am Acad Child Adolesc Psychiatry, 2008.

23. Carucci S, et al. Long-term efficacy and safety of stimulants for ADHD: a qualitative review. 2024.

24. Humphreys KL, et al. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry, 2013.

25. Galimberti M, et al. Review of stimulant misuse and diversion prevalence. 2024.

Du Rietz E, et al. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. Lancet Psychiatry, 2021.